LongBio Pharma (Suzhou) Co., Ltd. (HKG:1779)

Hong Kong · Delayed Price · Currency is HKD

105.80

+5.10 (5.06%)

Sep 30, 2026, 4:08 PM HKT

LongBio Pharma (Suzhou) Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Income	-219.3	-164.31	-109.4	-81.55
Net Income	-216.18	-175.58	-137.32	-95.78
Earnings Per Share	-3.50	-3.10	-2.89	-2.24
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	1,223	190.26	106.72	117.23
Total Debt	56.33	37.92	447.68	315.03
Net Cash (Debt)	1,167	152.34	-340.96	-197.81
Net Cash Growth	-	-	-	-
Net Cash Per Share	18.91	2.69	-7.18	-4.62

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-167.16	-121.04	-104.12	-60.87
Capital Expenditures	-3.88	-4.39	-6.15	-2.47
Free Cash Flow	-171.04	-125.43	-110.27	-63.34
Free Cash Flow Growth	-	-	-	-